
Agenus (AGEN) Stock Forecast & Price Target
Agenus (AGEN) Analyst Ratings
Bulls say
Agenus Inc has demonstrated a positive financial performance, reporting collaboration revenue of $26.8 million for 4Q24, an increase from $25.1 million in the previous quarter, highlighting its ability to generate consistent revenue growth. The company is executing strategic cost reductions, projecting a 60% decrease in annual external expenditures for 2025, which suggests improved operational efficiency and financial health. Furthermore, encouraging clinical activity has been observed, particularly for its antibody candidates, with high rates of partial responses in ongoing trials, strengthening the company's position in the competitive biopharmaceutical landscape.
Bears say
Agenus Inc. reported operating expenses of $28.7 million, reflecting a roughly 50% decline from the previous quarter, significantly exceeding prior estimates. The financial outlook remains negative due to several inherent risks, including potential safety issues in clinical programs, efficacy falling short of expectations, and substantial competition in the oncology space, alongside an anticipated need for approximately $300 million to $700 million in additional financing through 2037. Moreover, the company's shift towards investigator-sponsored trials and the need for a large Phase 3 trial for its lead candidates may further delay approval and necessitate significant capital investment, compounding the challenges facing its financial stability.
This aggregate rating is based on analysts' research of Agenus and is not a guaranteed prediction by Public.com or investment advice.
Agenus (AGEN) Analyst Forecast & Price Prediction
Start investing in Agenus (AGEN)
Order type
Buy in
Order amount
Est. shares
0 shares